D
Description
Biotech spin-out from the University of Wolverhampton, founded in 2017. Pioneering the development of expedited and cost-effective treatments for rare cancers, specifically Malignant Mesothelioma. Has developed GMP-quality PLGA-encapsulated disulfiram microparticles for intraperitoneally injectable localized therapy. Technology protected by recently granted patents.